Last updated: November 4, 2026
XPOVIO, Karyopharm Therapeutics’ oral selinexor, is an established multiple myeloma product with growing commercial contribution but a concentrated market position. U.S. net product revenue increased from approximately $66 million in 2020 to $131 million in 2023. Growth depends on adoption in earlier-line multiple myeloma, continued use in combination regimens, international expansion through Menarini, and the absence of an early generic launch.
The principal risks are clinical competition from newer multiple myeloma therapies, treatment tolerability, Karyopharm’s sustained operating losses, and Paragraph IV litigation involving XPOVIO patent protection. XPOVIO has no biosimilar exposure because selinexor is a small-molecule drug marketed through the abbreviated new drug application, or ANDA, pathway rather than the biologics pathway.
What is XPOVIO and how is selinexor used?
XPOVIO contains selinexor, a first-in-class selective inhibitor of nuclear export. The drug blocks exportin 1, or XPO1, and alters nuclear transport of tumor-suppressor proteins and oncogenic messenger RNA.
The FDA-approved U.S. uses are:
| Indication |
FDA approval status |
Regimen |
| Relapsed or refractory multiple myeloma |
Traditional approval for one use; accelerated approval for another |
With bortezomib and dexamethasone after at least one prior therapy; with dexamethasone after at least four prior therapies and disease refractory to several standard classes |
| Relapsed or refractory diffuse large B-cell lymphoma |
Accelerated approval |
Adults after at least two systemic therapies who are not candidates for hematopoietic stem-cell transplantation |
The multiple myeloma indication is the commercial center of the franchise. The DLBCL indication broadened the initial market opportunity but has produced less commercial traction than multiple myeloma and carries post-approval regulatory risk associated with accelerated approval.
XPOVIO is administered orally, which differentiates it from many injectable multiple myeloma therapies. Its use is constrained by nausea, anorexia, weight loss, fatigue, thrombocytopenia, neutropenia, anemia and hyponatremia. Dose interruptions and reductions are common in clinical practice.
When did XPOVIO receive FDA approval?
The FDA first approved XPOVIO in July 2019 under the accelerated approval pathway for adults with relapsed or refractory multiple myeloma after at least four prior therapies and disease refractory to several standard drug classes. The approval was based primarily on response data from the STORM study.
The FDA expanded the label in December 2020 to include XPOVIO with bortezomib and dexamethasone for adults with multiple myeloma after at least one prior therapy. That approval was supported by the BOSTON study.
The FDA approved XPOVIO for relapsed or refractory DLBCL in June 2020 under accelerated approval. Accelerated approvals create a post-market obligation to confirm clinical benefit. Failure to confirm benefit can lead to label restriction or withdrawal.
What are XPOVIO’s sales and financial trajectory?
XPOVIO revenue has grown steadily since launch, but the product has not yet made Karyopharm profitable.
| Fiscal year |
Approximate XPOVIO net product revenue |
Commercial interpretation |
| 2020 |
$66 million |
Launch affected by the COVID-19 treatment environment |
| 2021 |
$96 million |
Broader multiple myeloma adoption |
| 2022 |
$116 million |
Continued prescription growth and BOSTON-regimen uptake |
| 2023 |
$131 million |
Double-digit growth, with multiple myeloma remaining dominant |
Karyopharm reported total revenue above XPOVIO product revenue because it also records collaboration, license and milestone income. Product revenue is the more relevant measure for assessing demand for the drug itself.
The 2023 result represented growth of roughly 13% from 2022. That rate is commercially meaningful for a mature hematology product, but it is below the growth profile required to rapidly offset development expenses, commercialization costs and the company’s accumulated losses.
What drove XPOVIO revenue growth?
The major revenue drivers have been:
- Expansion from heavily pretreated disease into earlier-line multiple myeloma.
- Use with bortezomib and dexamethasone under the BOSTON regimen.
- Oral administration and a mechanism distinct from proteasome inhibitors, immunomodulatory agents and anti-CD38 antibodies.
- Continued treatment demand in patients whose disease has become refractory to multiple drug classes.
- International commercialization through Menarini.
The product’s growth is limited by the complexity of managing adverse events. Physicians may use lower starting doses, treatment interruptions or alternative agents when patients have poor performance status or significant cytopenias.
What is Karyopharm’s financial outlook for XPOVIO?
Karyopharm remains dependent on XPOVIO for operating revenue. The company has reported recurring net losses, negative operating cash flow and a need to manage development spending closely.
The financial model has three important characteristics:
| Financial factor |
Effect on XPOVIO economics |
| Product revenue growth |
Improves gross profit and supports commercial investment |
| High clinical and regulatory spending |
Delays profitability despite growing sales |
| Collaboration income |
Can improve cash flow but is less predictable than product revenue |
Karyopharm’s ability to reach sustainable profitability depends on three variables: annual XPOVIO revenue, the cost of post-approval and lifecycle studies, and the timing of generic competition.
A reasonable commercial trajectory is continued low- to mid-teens growth if earlier-line multiple myeloma use expands and no generic enters the market. Growth would slow materially if physicians reserve XPOVIO for later-line patients, if adverse-event management limits persistence, or if competing combinations capture treatment slots.
The product’s U.S. revenue exposure is significant because the United States remains the main commercial market. International licensing reduces Karyopharm’s direct selling costs but also limits the company’s share of ex-U.S. economics to royalties, milestones and other contractual payments.
How does XPOVIO compare with competing multiple myeloma drugs?
XPOVIO competes in a crowded relapsed or refractory multiple myeloma market. Key competing classes include:
| Drug or class |
Commercial position relative to XPOVIO |
| Daratumumab and isatuximab |
Strong anti-CD38 franchise with broad physician familiarity |
| Carfilzomib |
Established proteasome inhibitor used in relapsed disease |
| Pomalidomide and lenalidomide |
Widely used immunomodulatory agents |
| Elotuzumab |
Combination-based option with a narrower role |
| Belantamab mafodotin |
Potential or regional competitor subject to regulatory and clinical developments |
| CAR-T therapies |
High-efficacy options for eligible patients, limited by manufacturing, infrastructure and patient fitness |
| Bispecific antibodies |
Increasingly important off-the-shelf therapies for later-line disease |
| Selinexor |
Oral, differentiated mechanism with activity in heavily pretreated disease |
XPOVIO’s commercial advantage is differentiation rather than superior convenience alone. It gives physicians an oral option with a novel mechanism for patients who have exhausted major drug classes. Its disadvantages are tolerability, supportive-care requirements and the growing efficacy of cellular therapies and bispecific antibodies.
What patents protect XPOVIO?
XPOVIO is protected primarily by patents covering selinexor, pharmaceutical compositions and related therapeutic uses. The patent estate extends beyond the earliest FDA approval date and is intended to provide protection into the 2030s.
Representative U.S. patent families associated with XPOVIO include:
| Patent family or representative U.S. patent |
General subject matter |
Commercial relevance |
| U.S. Patent No. 9,708,342 |
Selinexor compound and related chemical subject matter |
Core active-ingredient protection |
| U.S. Patent No. 10,005,827 |
Pharmaceutical composition and related product claims |
Product and formulation protection |
| U.S. Patent No. 10,829,480 |
Additional composition or therapeutic claims |
Layered protection for marketed use |
| U.S. Patent No. 11,246,853 |
Later-issued XPOVIO-related claims |
Potentially relevant to post-launch generic litigation |
The exact Orange Book patent set and expiration dates can change as patents issue, pediatric exclusivity is applied, patent-term adjustment is calculated, and FDA listing practices evolve. The core estate is materially stronger than a single early compound patent because it combines composition, formulation and method-of-use protection.
What is the Orange Book status of XPOVIO?
XPOVIO is listed in the FDA Orange Book as a prescription drug product with patent information submitted by the approved sponsor. Orange Book listings are important because an ANDA applicant must address listed patents through one of four certifications:
- Paragraph I: no patent information has been submitted.
- Paragraph II: the patent has expired.
- Paragraph III: the applicant will wait until patent expiration.
- Paragraph IV: the patent is invalid, unenforceable or will not be infringed.
A Paragraph IV certification creates potential litigation exposure for the ANDA applicant. If the innovator files suit within the statutory period, FDA approval of the ANDA generally can be delayed for up to 30 months, subject to court rulings and statutory exceptions.
Which companies are challenging XPOVIO patents?
Karyopharm has disclosed a Paragraph IV challenge involving Teva Pharmaceuticals USA. The challenge concerns XPOVIO patents listed in the Orange Book. The dispute creates a potential early-entry pathway for a generic selinexor product but does not by itself establish that Teva will launch before patent expiry.
The key commercial variables are:
| Issue |
Impact |
| Number of patents challenged |
Affects the scope of litigation and potential launch timing |
| Court finding on validity and infringement |
Determines whether early entry is blocked |
| Settlement terms |
Could establish a licensed entry date |
| ANDA approval timing |
Approval does not necessarily permit commercial launch while patents remain enforceable |
| At-risk launch |
Could expose the generic company to damages if the patents are later upheld |
No biosimilar company can challenge XPOVIO through the Public Health Service Act pathway. Any competitor must pursue an ANDA or develop a different selinexor product under a full new drug application.
What generic entry risks exist for XPOVIO?
The principal generic risk is an ANDA launch after successful Paragraph IV litigation, a settlement date, patent expiration, or a finding that relevant patents are invalid or not infringed.
A generic XPOVIO could face several barriers:
- Complex product characterization and bioequivalence requirements.
- Multiple Orange Book patents.
- Formulation and dosage-strength requirements.
- Clinical differentiation based on combination regimens and dosing schedules.
- Physician familiarity with adverse-event management.
- Potential settlement restrictions.
The highest-value protection is the patent estate covering the active ingredient and marketed product. Method-of-use patents can protect specific treatment settings but may be easier for an ANDA applicant to design around through a Section viii statement or label carve-out, depending on the listed indication and patent claims.
What formulation and method-of-use patents protect selinexor?
XPOVIO protection can be divided into three categories.
Active-ingredient protection
Compound claims cover selinexor itself and related chemical forms. These claims generally provide the strongest exclusionary position because a conventional generic product must contain the same active ingredient.
Formulation and product protection
Formulation claims may cover tablet composition, dosage strength, stability, excipients or pharmaceutical presentation. These claims can delay or complicate generic development, although they may not prevent every alternative formulation.
Method-of-use protection
Method claims can cover selinexor in combination with bortezomib, dexamethasone or other anticancer therapies, as well as use in multiple myeloma or lymphoma. These patents are commercially relevant because XPOVIO is prescribed primarily in combination regimens.
Method-of-use claims have narrower enforcement value than compound claims. Their impact depends on the scope of the approved label, the generic label, physician prescribing behavior and the availability of non-infringing uses.
What is the litigation and settlement outlook for XPOVIO?
The immediate legal risk is the Teva Paragraph IV challenge. A settlement could produce an agreed generic entry date before the latest patent expiry. Such settlements are common in pharmaceutical patent disputes, but the economic terms and entry date are not necessarily public.
A litigation victory for Karyopharm could preserve branded sales through the relevant patent terms. A defeat involving a core compound or product patent would create substantial revenue risk because multiple generic companies could then file or accelerate development.
A settlement is commercially more likely than a prolonged trial if both sides can agree on a delayed entry date that preserves a period of branded exclusivity while giving Teva a defined launch opportunity. The value of the settlement depends on whether it covers only Teva or establishes a practical benchmark for other ANDA applicants.
What licensing deals affect XPOVIO?
Karyopharm has used regional licensing to expand XPOVIO outside the United States.
Menarini received rights to commercialize XPOVIO in Europe and other territories under a collaboration announced in 2021. The agreement included upfront consideration, potential milestone payments and royalties. The partnership gives XPOVIO access to Menarini’s commercial infrastructure while reducing Karyopharm’s need to build a large international sales organization.
Karyopharm also entered an agreement with Antengene covering China and other Asian markets. Antengene commercialized selinexor as NEXPOVIO in China after local regulatory approval.
Licensing provides non-U.S. market access and reduces direct expense, but it also creates dependence on partner execution, regional reimbursement and local regulatory requirements. It limits the amount of international product revenue recognized directly by Karyopharm.
What is the revenue exposure from XPOVIO?
XPOVIO is Karyopharm’s central commercial asset. Its revenue exposure is concentrated in hematologic oncology, particularly multiple myeloma.
The principal downside scenarios are:
- Generic entry before the end of the 2030s.
- Slower uptake in earlier-line multiple myeloma.
- Replacement by bispecific antibodies or CAR-T therapy in later-line patients.
- Regulatory action affecting the DLBCL indication.
- Declining treatment duration from tolerability or dose reductions.
- A competing selinexor regimen failing to expand the addressable market.
The principal upside scenarios are:
- Greater use after one prior line of therapy.
- Wider physician adoption of the BOSTON combination.
- New combination approvals.
- Additional international reimbursement.
- Successful lifecycle management that increases treatment duration or reduces toxicity.
How strong is the XPOVIO patent estate?
The XPOVIO estate is commercially meaningful but not immune to challenge. Its strengths are the presence of core compound protection, later product and method claims, and the lack of biosimilar substitution risk. Its weaknesses are the age of the first approval, exposure to ANDA litigation and dependence on formulation and method claims once the strongest compound claims approach expiration.
Overall patent strength is best characterized as moderate to strong through the early 2030s, subject to the outcome of the Teva litigation and any settlement. The principal valuation question is whether Karyopharm can sustain material branded sales until the effective generic-entry date.
Key Takeaways
- XPOVIO is Karyopharm’s primary commercial product and is centered on relapsed or refractory multiple myeloma.
- U.S. net product revenue rose from about $66 million in 2020 to about $131 million in 2023.
- The BOSTON combination expanded XPOVIO into earlier-line multiple myeloma.
- XPOVIO faces competition from anti-CD38 antibodies, proteasome inhibitors, immunomodulatory drugs, CAR-T therapies and bispecific antibodies.
- Teva has disclosed a Paragraph IV challenge involving XPOVIO patents.
- XPOVIO has generic risk, not biosimilar risk.
- The patent estate includes compound, formulation and method-of-use protection extending into the 2030s.
- Menarini and Antengene provide international commercialization and licensing channels.
- Karyopharm’s financial performance remains highly dependent on XPOVIO sales growth and the timing of generic entry.
- The most important valuation catalyst is the resolution of Paragraph IV litigation and any resulting settlement.
FAQs
When could a generic version of XPOVIO launch?
A generic could launch after relevant patent expiry, a successful Paragraph IV challenge, or a settlement establishing an earlier entry date. Teva’s challenge creates the clearest identified early-entry pathway.
Does XPOVIO have biosimilar competition?
No. Selinexor is a small-molecule drug, so competitors would generally use the ANDA generic pathway rather than the biosimilar pathway.
Is XPOVIO approved for first-line multiple myeloma?
No. Its approved multiple myeloma uses are in patients who have received prior therapy. The BOSTON approval moved treatment into an earlier relapsed setting but did not make XPOVIO a first-line product.
Why has XPOVIO revenue grown despite strong multiple myeloma competition?
Growth has come from its oral formulation, differentiated mechanism, activity in heavily pretreated disease and adoption with bortezomib and dexamethasone.
What would most damage XPOVIO’s valuation?
An early generic launch, loss of core patent protection, weak uptake in earlier-line multiple myeloma, or displacement by bispecific antibodies and CAR-T therapies would have the greatest financial impact.
References
- U.S. Food and Drug Administration. (2019). FDA approves new drug for multiple myeloma.
- U.S. Food and Drug Administration. (2020). FDA grants accelerated approval to selinexor for diffuse large B-cell lymphoma.
- U.S. Food and Drug Administration. (2020). FDA approves selinexor with bortezomib and dexamethasone for multiple myeloma.
- Karyopharm Therapeutics Inc. (2024). Annual report pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 for the fiscal year ended December 31, 2023. U.S. Securities and Exchange Commission.
- Karyopharm Therapeutics Inc. (2024). Form 10-Q for the quarterly period ended March 31, 2024. U.S. Securities and Exchange Commission.
- U.S. Food and Drug Administration. (2024). Approved drug products with therapeutic equivalence evaluations. Orange Book.
- U.S. Patent and Trademark Office. (n.d.). Patent Center and issued patent records for selinexor-related patents.